A pivotal phase III study of Hydroxyprogesterone caproate (LPCN-1107) in reducing the risk of preterm birth (PTB) in women with singleton pregnancy who have a history of singleton spontaneous PTB.

Trial Profile

A pivotal phase III study of Hydroxyprogesterone caproate (LPCN-1107) in reducing the risk of preterm birth (PTB) in women with singleton pregnancy who have a history of singleton spontaneous PTB.

Planning
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Hydroxyprogesterone (Primary) ; Hydroxyprogesterone
  • Indications Preterm birth
  • Focus Registrational; Therapeutic Use
  • Sponsors Lipocine
  • Most Recent Events

    • 26 Jun 2017 According to a company media release, Lipocine has submitted a Special Protocol Assessment ("SPA") request to the U.S. Food and Drug Administration as part of the ongoing interaction with the FDA on the detailed design of the planned Phase 3 clinical development program for LPCN 1107 for prevention of recurrent preterm birth ("PTB") with history of singleton pregnancy.
    • 11 Mar 2017 New trial record
    • 06 Mar 2017 According to a Lipocine media release, the company plans to submit the LPCN-1107 Phase 3 protocol to the FDA via a Special Protocol Assessment (SPA) in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top